MOTS-c Safety Questions: What Studies Report

MOTS-c is a short mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Public interest in it is dominated by safety questions: whether it interacts with cancer biology, what it does to blood glucose, and whether specific organs or populations have been studied. This page summarises what the peer-reviewed records listed in the references actually stated, organised by model and by finding, and says plainly where no human data exist. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

The evidence base: What Studies Report

The records summarised here are laboratory studies in cells and rodents plus narrative reviews. A 2023 review in Frontiers in Endocrinology framed MOTS-c as a mitochondrial-derived peptide for therapeutic exploitation, that is, as a research target rather than an established therapy, and a 2023 review in Metabolites summarised its role in preventing metabolic disorders in experimental settings. Both were reviews of preclinical work rather than reports of human trials.

An important structural point for anyone reading safety questions: the primary studies in this set were designed around efficacy endpoints — glucose handling, muscle mass, tumour growth, viral replication, cartilage integrity. Papers such as the 2015 Cell Metabolism obesity and insulin resistance study (PMID 25738459) and the 2024 iScience muscle study (PMID 39559755) reported mechanism and outcome in animals and cells; they were not toxicology studies and did not exist to characterise a human adverse-event profile. Absence of an adverse-event discussion in an efficacy paper is not the same as a demonstration of safety.

Human safety data: What Studies Report

None of the records in the reference list below described a controlled clinical trial in humans reporting adverse events, dropout rates, or laboratory safety monitoring for administered MOTS-c. The 2023 Frontiers in Endocrinology review discussed the peptide as a candidate for future therapeutic exploitation, and the 2023 Metabolites review discussed metabolic disorder prevention on the basis of experimental models. Readers looking for human tolerability data — dose-limiting effects, immunogenicity, injection-site findings, long-term exposure outcomes — will not find them in this literature set.

Cancer questions: What Studies Report

The most common safety search in this area asks whether a peptide that improves mitochondrial function might also support tumour growth. The one oncology record in this set pointed the other way. A 2024 study in Advanced Science reported that MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination, describing a specific molecular route by which the peptide restrained tumour cell behaviour in laboratory models.

Several limits apply to that finding. The study addressed ovarian cancer models specifically; researchers did not report results across other tumour types in that paper, and a suppressive result in one lineage does not generalise to all cancers. There were no human oncology outcomes, no data in people with a cancer history, and no interaction data with chemotherapy or radiotherapy in that report. A separate 2024 study in Journal of Agricultural and Food Chemistry examined radiation biology from a different angle, reporting that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner — there MOTS-c functioned as a required mediator of another compound's protective effect, not as an administered therapy for cancer.

Blood glucose and metabolic effects: What Studies Report

The metabolic literature is the oldest and largest part of the MOTS-c record, and it matters to safety questions because a glucose-lowering direction of effect is pharmacologically relevant in anyone whose glucose is already regulated by other means.

• The 2015 Cell Metabolism study reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in experimental models.
• A 2022 study in Pharmacological Research reported that MOTS-c relieved hyperglycemia and insulin resistance in gestational diabetes mellitus models.
• A 2025 study in Experimental & Molecular Medicine reported that the peptide prevented pancreatic islet cell senescence and delayed diabetes in its model system.
• The 2023 Metabolites review collated experimental evidence that MOTS-c functionally prevents metabolic disorders.

What researchers did not report in these abstracts: hypoglycaemia rates, behaviour in normoglycaemic subjects over long periods, or interaction data with glucose-lowering drugs. The models were disease models — obese, insulin-resistant, hyperglycaemic or ageing systems — which is a different question from what happens in a metabolically healthy organism.

Pregnancy and gestational contexts: What Studies Report

Only one record in this set touched pregnancy biology: the 2022 Pharmacological Research study of hyperglycemia and insulin resistance in gestational diabetes mellitus. That study reported a metabolic benefit in its experimental context; it was not a reproductive toxicology study and did not report fetal outcome safety data in humans. No record here reported human pregnancy exposure, lactation data, or fertility endpoints.

Skeletal muscle: What Studies Report

Three records addressed muscle. A 2024 iScience study reported that MOTS-c modulated skeletal muscle function by directly binding and activating CK2, identifying a direct protein target. A 2024 study in the American Journal of Physiology — Endocrinology and Metabolism reported that the microprotein attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. A 2022 study in Peptides reported that MOTS-c promoted muscle differentiation in vitro.

From a safety-reading perspective, the CK2 finding is the notable one: CK2 is a widely expressed kinase, so a peptide that binds and activates it has the potential for effects beyond the tissue under study. The study reported the binding interaction and its muscle consequences (PMID 39559755); it did not characterise off-target consequences of that interaction across other tissues, and no record in this set followed that question up in humans.

Liver and viral infection: What Studies Report

A 2024 study in Gut reported a novel function of MOTS-c in mitochondrial remodelling that contributed to an antiviral role during hepatitis B virus infection. That paper described a host-defence mechanism in an infection model. It did not report hepatotoxicity screening, liver enzyme monitoring in humans, or behaviour in people with established liver disease.

Joints and cartilage: What Studies Report

A 2025 study in Free Radical Biology & Medicine reported that MOTS-c attenuated mitochondrial dysfunction, pyroptosis and cartilage degradation in osteoarthritis through an Nrf2-dependent mechanism. As with the other organ-specific work, the endpoints were disease-model outcomes rather than safety endpoints, and the mechanism reported was pathway-level rather than clinical.

Findings by model: What Studies Report

Doses and durations: What Studies Report

Dosing regimens differed substantially across these models — species, route and duration were not comparable between an in vitro differentiation experiment (PMID 35842023) and an in vivo metabolic study (PMID 25738459). This page therefore reports direction of effect rather than restating numeric regimens, because animal exposures do not translate to human exposures and no human dose-finding or dose-tolerability study appears in this reference set.

Populations and questions with no data in this literature

• Humans of any kind — no controlled trial with safety endpoints appears among these records; the reviews described the field as preclinical and exploratory (PMID 36761202, PMID 36677050).
• People with cancer — the ovarian model reported tumour suppression (PMID 39321430); no human oncology safety or interaction data were reported.
• Human pregnancy and lactation — only a gestational diabetes model was reported (PMID 34798268).
• Renal or hepatic impairment — the liver record concerned antiviral mechanism, not clearance or hepatotoxicity (PMID 37788894).
• Children and adolescents — no record in this set addressed pediatric biology.
• Drug interactions and long-term exposure — not addressed by any record listed here.

Reading this literature critically

Three habits help when safety questions are searched online. First, check the model: a result in immortalised cells (PMID 35842023) carries different weight from a result in a whole animal (PMID 38170165). Second, check whether the peptide was administered or merely required: in the radiation lung injury work, the study reported that another compound's protection was MOTS-c-dependent (PMID 39259217). Third, check whether the paper measured safety at all — most of these did not, because they were mechanistic efficacy studies.

MOTS-c is not an approved drug product. Research-use-only materials are not manufactured, tested or labelled for human administration, and regulatory status is separate from what any laboratory study reported. This page is for educational purposes only and is not medical advice; consult a licensed physician about any individual health question.

References

• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology — Endocrinology and Metabolism, 2024)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)